Current Status of PSMA-Targeted Radioligand Therapy in the Era of Radiopharmaceutical Therapy Acquiring Marketing Authorization.

MLA

Oh, So Won, et al. “Current Status of PSMA-Targeted Radioligand Therapy in the Era of Radiopharmaceutical Therapy Acquiring Marketing Authorization.” Nuclear Medicine and Molecular Imaging, vol. 56, no. 6, Dec. 2022, pp. 263–81. EBSCOhost, https://doi.org/10.1007/s13139-022-00764-4.

APA

Oh, S. W., Suh, M., & Cheon, G. J. (2022). Current Status of PSMA-Targeted Radioligand Therapy in the Era of Radiopharmaceutical Therapy Acquiring Marketing Authorization. Nuclear Medicine and Molecular Imaging, 56(6), 263–281. https://doi.org/10.1007/s13139-022-00764-4

Chicago

Oh, So Won, Minseok Suh, and Gi Jeong Cheon. 2022. “Current Status of PSMA-Targeted Radioligand Therapy in the Era of Radiopharmaceutical Therapy Acquiring Marketing Authorization.” Nuclear Medicine and Molecular Imaging 56 (6): 263–81. doi:10.1007/s13139-022-00764-4.